[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053403":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":37,"locations":43,"responsibleParty":58,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":25,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":25,"overallStatus":80,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Beijing QL Biopharmaceutical Co.,Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"cohort1 ZT002 injection","EXPERIMENTAL","Participants will receive 8 study interventions. The study interventions will be administered during treatment periods starting on Days 1, 15, 29, 43, 57, 71, 85 and 99.",[13],"Drug: ZT002 injection",{"label":15,"type":10,"description":16,"interventionNames":17},"cohort2 ZT002 injection matching placebo","Participants will receive 8 matching placebo interventions. The interventions will be administered during treatment periods starting on Days 1, 15, 29, 43, 57, 71, 85 and 99.",[18],"Drug: ZT002 injection matching placebo",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ZT002 injection","Subjects will receive subcutaneous injections of Zovaglutide (ZT002 Injection) once every two weeks.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"ZT002 injection matching placebo","Subjects will receive subcutaneous injections of ZT002 injection matching placebo once every two weeks.",[15],[31,35],{"name":32,"affiliation":33,"role":34},"Quankun Zhuang, Doctor","Beijing GoBroad Hospital","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":33,"role":34},"Xuemei Liu, Doctor",[38],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Li Liu","CONTACT","+86-13911711598","liu.li@qlbiopharm.com",[44],{"facility":33,"status":25,"city":45,"state":25,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Beijing","102200","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56],{"name":57,"role":40,"phone":25,"phoneExt":25,"email":25},"Quankun Zhuang, Master",{"type":59,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100053403","phase-1-a-study-to-investigate-the-effects-of-zovaglutide-zt002-injection-on-qtc-interval-in-healthy-adults-100053403",false,"NCT07697846","A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults","Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled（Concentration）-QTc（C-QTc）Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects","Inclusion Criteria:\n\n* Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;\n* Age between 18 - 45 years (both inclusive) at the time of signing of the informed consent;\n* Male (body weight \\>60.0 kg) or female (body weight \\>55.0 kg). Body mass index (BMI) 24.0 - 35.0 kg\u002Fm²(both inclusive);\n\nExclusion Criteria:\n\n* Known hypersensitivity (asthma, hypersensitivity to GLP-1 receptor agonists or excipients), or known hypersensitivity to ZT002 injection;\n* History of acute or chronic pancreatitis, or pancreatic injury.History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.\n* Has a history of cardiovascular diseases or risk factors predisposing to torsades de pointes (TdP); has personal or family history of any cardiac conduction abnormalities; has personal or family history of long QT syndrome (LQTS); or has a family history of sudden cardiac death.\n* Those with any type of malignant tumors within 5 years prior to screening (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).\n* Medical history of hypoglycemia within 6 months before screening;\n* History of acute or chronic pancreatitis;\n* ECG findings exceeding thresholds at screening or prior to randomization: PR interval \\>220 ms, QRS duration \\>110 ms, heart rate (HR) \\\u003C50 bpm or \\>100 bpm, QTcF ≥450 ms; or presence of any ECG abnormalities deemed clinically significant by the investigator.\n* Glycated hemoglobin (HbA1c) ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol\u002FL at screening;\n* Aspartate aminotransferase \\> 2 × upper limit of normal (ULN), Alanine aminotransferase \\> 2 × ULN,\n* Alkaline phosphatase total bilirubin \\> 1.5 × ULN;\n* Subjects who have previously undergone gastric bariatric surgery or other weight-loss surgeries, or who plan to receive weight-loss surgery, liposuction, abdominal lipectomy, or other procedures with substantial impacts on body weight during the study.\n* Use of weight-altering medications or therapies within 3 months prior to screening.\n* Administration of any medications known to prolong QT\u002FQTc interval, alter heart rate, or carry risks of torsades de pointes (TdP) within 4 weeks prior to screening\n* Pregnant or lactating women, or subjects with a positive pregnancy test result at screening\u002Fbaseline",true,"ALL","18 Years","45 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"PHASE1","This study is designed to investigate the effect of treatment with Zovaglutide (ZT002 Injection) on the corrected cardiac QT interval relative to a placebo control in healthy participants.",[79],"Overweight, Obesity","NOT_YET_RECRUITING","2026-07-06",{"date":83,"type":84},"2026-07-13","ACTUAL",{"date":86,"type":73},"2026-07-18",{"date":88,"type":73},"2027-03-24",{"name":5,"class":6},1]